Raymond James Financial Services Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Raymond James Financial Services Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$2.9M	Buy	61,783 +4,352	+8%	+$221K	﹤0.01%	1525
2024 Q2	$3.1M	Buy	57,431 +11,391	+25%	+$659K	﹤0.01%	1426
2024 Q1	$3.14M	Buy	46,040 +6,623	+17%	+$474K	﹤0.01%	1399
2023 Q4	$2.47M	Buy	39,417 +6,039	+18%	+$334K	﹤0.01%	1461
2023 Q3	$1.52M	Buy	33,378 +5,948	+22%	+$307K	﹤0.01%	1664
2023 Q2	$1.54M	Sell	27,430 -1,937	-7%	-$110K	﹤0.01%	1666
2023 Q1	$1.33M	Buy	29,367 +2,102	+8%	+$102K	﹤0.01%	1729
2022 Q4	$1.11M	Buy	27,265 +985	+4%	+$52.3K	﹤0.01%	1774
2022 Q3	$1.72M	Buy	26,280 +5,498	+26%	+$398K	﹤0.01%	1504
2022 Q2	$1.26M	Sell	20,782 -3,568	-15%	-$210K	﹤0.01%	1693
2022 Q1	$1.53M	Sell	24,350 -13,140	-35%	-$825K	﹤0.01%	1671
2021 Q4	$2.84M	Buy	37,490 +8,018	+27%	+$700K	0.01%	1312
2021 Q3	$3.3M	Buy	29,472 +9,564	+48%	+$1.2M	0.01%	1201
2021 Q2	$3.22M	Sell	19,908 -7,834	-28%	-$953K	0.01%	1201
2021 Q1	$3.38M	Buy	27,742 +6,044	+28%	+$913K	0.01%	1104
2020 Q4	$3.32M	Buy	21,698 +6,431	+42%	+$760K	0.01%	1018
2020 Q3	$1.28M	Buy	15,267 +2,560	+20%	+$227K	﹤0.01%	1398
2020 Q2	$934K	Buy	12,707 +1,883	+17%	+$110K	﹤0.01%	1531
2020 Q1	$459K	Buy	10,824 +37	+0.3%	+$1.91K	﹤0.01%	1611
2019 Q4	$657K	Buy	10,787 +1,673	+18%	+$91.3K	﹤0.01%	1798
2019 Q3	$374K	Buy	9,114 +611	+7%	+$29.2K	﹤0.01%	2091
2019 Q2	$400K	Buy	8,503 +1,102	+15%	+$44K	﹤0.01%	2072
2019 Q1	$264K	Sell	7,401 -110	-1%	-$3.8K	﹤0.01%	2335
2018 Q4	$215K	Sell	7,511 -5,503	-42%	-$191K	﹤0.01%	2207
2018 Q3	$577K	Hold	13,014	–	–	﹤0.01%	1809
2018 Q2	$765K	Buy	+13,014	New	+$741K	﹤0.01%	1594

Other funds holding CRSP

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Raymond James Financial Services Advisors's CRSP Position: Q3 2024 in Review

Raymond James Financial Services Advisors increased its CRISPR Therapeutics (CRSP) stake by 7.6% in Q3 2024, buying an estimated $221K and bringing the position to 61,783 shares worth $2.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1525.

Raymond James Financial Services Advisors first reported a position in CRSP in Q2 2018 and has held it in 26 quarters since. The position peaked at $3.38M in Q1 2021. 416 funds tracked by Wall St. Rank hold CRSP as of Q3 2024.

Raymond James Financial Services Advisors held 61,783 shares of CRISPR Therapeutics worth $2.9M as of Q3 2024.
Raymond James Financial Services Advisors bought 4,352 CRISPR Therapeutics shares in Q3 2024, an estimated $221K.
CRISPR Therapeutics made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #1525 holding.
Raymond James Financial Services Advisors first reported a position in CRISPR Therapeutics in Q2 2018 and has held it in 26 quarters since.
Raymond James Financial Services Advisors's CRISPR Therapeutics position peaked at $3.38M in Q1 2021.
416 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.